Approach to and management of the acute stroke patient with atrial fibrillation: A literature review

Journal of Hospital Medicine

Volumn 3, Issue 4, 2008, Pages 326-332

  Marmagkiolis, Konstantinos ^a,b,e   Nikolaidis, Ioannis G ^c   Politis, Themos ^d   Goldstein, Lawrence ^b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b Western Reserve Care System   (United States)

^c TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^d Northeast Ohio Medical University   (United States)

^e NONE   (United States)

Author keywords

Arrhythmais and pacemakers; Evidence based medicine; Intracranial hemorrhage; Ischemic stroke; Valvular heart disease

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; EMBOLECTOMY; GENETIC ANALYSIS; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MONOTHERAPY; NEUROSURGERY; PATIENT CARE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SIDE EFFECT; STROKE; THROMBOSIS;

ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; ASPIRIN; ATRIAL FIBRILLATION; FACTOR VIIA; HEPARIN; HUMANS; INTRACRANIAL HEMORRHAGES; PLASMA; RECOMBINANT PROTEINS; STROKE; THROMBOLYTIC THERAPY; VITAMIN K; WARFARIN;

EID: 51649092181     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.343     Document Type: Review

References (66)

1. Mackay J, Mensah GA. The Atlas of Heart Disease and Stroke. Geneva, Switzerland: World Health Organization; 2004.
2. National Institute of Neurological Disorders and Stroke. NIH Stroke Scale. Available at: http://www.ninds.nih.gov/doctors/ NIH_stroke_scale_booklet.pdf. Accessed January 2008.
3. Royal College of Physicians. National Clinical Guidelines for Stroke. 2nd ed. Prepared by the Intercollegiate Stroke Working Party. London: RCP, 2004.
4. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5-10.
5. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141(10):745-752.
6. Kalra L, Lip GY. Antithrombotic treatment in atrial fibrillation. Heart. 2007;93(1):39-44.
7. Gage BF, Van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004; 110(16): 2287-2292.
8. Medi C, Hankey GJ, Freedman SB. Atrial fibrillation. Med J Aust. 2007;186(4):197-202.
9. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke. A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Stroke. 2007;38(5):1655-1711.
10. Hermier M, Nighoghossian N, Derex L, et al. MRI of acute post-ischemic cerebral hemorrhage in stroke patients: diagnosis with T2*-weighted gradient-echo sequences. Neuroradiology. 2001;43(10):809-815.
11. Desal HA, Auffray-Calvier E, Guillon B, et al. Emergency imaging of cerebrovascular accidents. J Neuroradiol. 2004; 31(4):327-333.
12. Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults. 2007 update. A guideline from the American Heart Association, American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007;38(6):2001-2023.
13. Tan JC, Dillon WP, Liu S, Adler F, Smith WS, Wintermark M. Systematic comparison of perfusion-CT and CT-angiography in acute stroke patients. Ann Neurol. 2007;61(6):533-543.
14. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 suppl):S483-S512.
15. Goldstein LB. Acute ischemic stroke treatment in 2007. Circulation. 2007;116(13):1504-1514.
16. Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC. Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter? Neurology. 2003;61(1): 71-75.
17. Egan R, Clark W, Lutsep H, Nesbit G, Barnwell S, Kellogg J. Efficacy of intraarterial thrombolysis of basilar artery stroke. J Stroke Cerebrovasc Dis. 1999;8(1):22-27.
18. Poncyljusz W, Falkowski A, Kojder I, et al. Treatment of acute ischemic brain infarction with the assistance of local intraarterial thrombolysis with recombinant tissue-type plasminogen activator. Acta Radiol. 2007;48(7): 774-780.
19. Tountopoulou A, Ahl B, Weissenborn K, Becker H, Goetz F. Intra-arterial thrombolysis using rt-PA in patients with acute stroke due to vessel occlusion of anterior and/or posterior cerebral circulation. Neuroradiology. 2008;50(1): 75-83.
20. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003;34:2847-2850.
21. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology. 2002;59:862-867.
22. Saqqur M, Uchino K, Demchuk AM, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke. 2007;38(3):948-954.
23. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E. Thrombolysis for acute ischemic stroke. Cochrane Database Syst Rev. 2003;(3):CD000213.
24. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
25. Smith MA, Shahar E, Doliszny KM, McGovern PG, Arnett DK, Luepker RV. Trends in medical care of hospitalized stroke patients between 1980 and 1990: the Minnesota stroke survey. J Stroke Cerebrovasc Dis. 1998;7(1):76-84.
26. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomized study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 2000;355(9211):1205-1210.
27. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. Lancet. 1997;349(9065):1569-1581.
28. Adams HP Jr. Emergent use of anticoagulation for treatment of patients with ischemic stroke. Stroke. 2002;33: 856-861.
29. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007;38(2):423-430.
30. Dippel DW. The results of CAPRIE, IST and CAST. International Stroke Trial. Chinese Acute Stroke Trial. Thromb Res 1998;92(1 suppl 1):S13-S16.
31. Van Kooten F, Ciabattoni G, Patrono C, Dippel DWJ, Koudstaal PJ. Platelet activation and lipid peroxidation in patients with acute ischemic stroke. Stroke. 1997;28:1557-1563.
32. Hylek M, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation elaine. N Engl J Med. 2003;349:1019-1026.
33. Waldo AL, Becker RC, Tapson VF, Colgan KJ. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46(9):1729-1736.
34. Ezekowltz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA. 1999;281(19):1830-1835.
35. Hart RG, Palacio, S. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke. 2002;33(11):2722-2727.
36. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc. 2004; 79(12):1495-1500.
37. Bertram M, Bonsanto M, Hacke W, Schwab S. Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. J Neurol. 2000;247 (3):209-214.
38. Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1-5.
39. Van der Meer FJM, Rosendaal FR, Vanderbroucke JP. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med. 1993;153:1557-1562.
40. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral aroyloid angiopathy: a genetic and pathologic study. Neurology. 20;55(7):947-951.
41. Hart RG, Kase CS, Freeman WD, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clinic Proc. 2007;82(1):82-92.
42. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost. 2006;4(5):967-970.
43. Appelboam R, Thomas EO. The headache over warfarin in British neurosurgical intensive care units: a national survey of current practice. Intensive Care Med. 2007;33(11):1946-1953.
44. Goldstein JN, Thomas SH, Frontiero V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke. 2006;37(1):151-155.
45. Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology. 2006;67(7):1272-1274.
46. Lorenz R, Kienast J, Otto U, et al. Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study. Blood Coagul Fibrinolysis. 2007;18(6):565-570.
47. O'Shaughnessy DF, Atterbury C, Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Hematol. 2004;126():11-28.
48. Ansel J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of vitamin K antagonists. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:204s-33s.
49. Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy. Comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37:1465.
50. Dunn CJ, Spencer CM. Recombinant factor VIIa. BioDrugs. 1999;12(1):71-77.
51. Diringer MN, Ferran JM, Broderick J, et al. Impact of recombinant activated factor VII on health-related quality of life after intracerebral hemorrhage. Cerebrovasc Dis. 2007;24(2-3):219-225.
52. Mayer SA, Brun NC, Broderick J, et al. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. Neurocrit Care. 2006;4(3):206-214.
53. Mendelow AD, Gregson BA, Fernandes HM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005; 365(9457): 387-397.
54. Thompson KM, Gerlach SY, Jorn HK, Larson JM, Brott TG, Files JA. Advances in the care of patients with intracerebral hemorrhage. Mayo Clin Proc. 2007;82(8):987-990.
55. Collice M, D'Aliberti G, Talamonti G, Bacigaluppi S. Surgery for intracerebral hemorrhage. Neurol Sci. 2004;25: s10-s11.
56. Nishihara T, Morita A, Teraoka A, Kirino T. Endoscopy-guided removal of spontaneous intracerebral hemorrhage: comparison with computer tomography-guided stereotactic evacuation. Childs Nerv Syst. 2007;23(6):677-683.
57. Thomassen L, Bakke SJ. Endovascular reperfusion therapy in acute ischaemic stroke. Acta Neurol Scand Suppl. 2007;187:22-29.
58. Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol. 2006;27(6):1177-1182.
59. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755-759.
60. Bayard YL, Ostermayer SH, Hein R, et al. Percutaneous devices for stroke prevention. Cardiovasc Revasc Med. 2007;8(3):216-225.
61. El-Chami MF, Hoffman M, Lerakis S. Sealing the left atrial appendage: ready for prime time? Am J Med Sci. 2007; 333(5):285-289.
62. Sick PB, Schuler G, Hauptmann KE, et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2007;49(13):1490-1495.
63. Onalan O, Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. Stroke. 2007;38(2 suppl):624-630.
64. FDA News. FDA clears genetic lab test for warfarin sensitivity. Available at: http://www.fda.gov/bbs/topics/news/2007/new01701.html. Accessed January 2008.
65. Ndegwa S. Pharmacogenomics and warfarin therapy. Issues Emerg Health Technol. 2007;(104):1-8.
66. Ross OA, Worrall BB, Meschia JF. Advancing stroke therapeutics through genetic understanding. Curr Drug Targets. 2007;8(7):850-859.